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Purpose: In patients with COPD, acute exacerbation (AE) is not only an important determinant of
prognosis, but also an important factor in choosing therapeutic agents. In this study, we evaluated
the usefulness of COPD subtypes identiﬁed through cluster analysis to predict the ﬁrst AE.
Patients and methods: Among COPD patients in the Korea COPD Subgroup Study
(KOCOSS) cohort, 1,195 who had follow-up data for AE were included in our study. We
selected seven variables for cluster analysis – age, body mass index, smoking status, history
of asthma, COPD assessment test (CAT) score, post-bronchodilator (BD) FEV1 % predicted,
and diffusing capacity of carbon monoxide % predicted.
Results: K-means clustering identiﬁed four clusters for COPD that we named putative asthma-
COPD overlap (ACO), mild COPD, moderate COPD, and severe COPD subtypes. The ACO
group (n=196) showed the second-best post-BD FEV1 (75.5% vs 80.9% [mild COPD, n=313] vs
52.4% [moderate COPD, n=345] vs 46.7% [severe COPD, n=341] predicted), the longest 6-min
walking distance (424 m vs 405 m vs 389 m vs 365 m), and the lowest CAT score (12.2 vs 13.7
vs 15.6 vs 17.5) among the four groups. ACO group had greater risk for ﬁrst AE compared to the
mild COPD group (HR, 1.683; 95% CI, 1.175–2.410). The moderate COPD and severe COPD
group HR values were 1.587 (95% CI, 1.145–2.200) and 1.664 (95% CI, 1.203–2.302), respec-
tively. In addition, St. George’s Respiratory Questionnaire score (HR: 1.019; 95% CI,
1.014–1.024) and gastroesophageal reﬂux disease were independent factors associated with the
ﬁrst AE (HR: 1.535; 95% CI, 1.116–2.112).
Conclusion: Our cluster analysis revealed an exacerbator subtype of COPD independent of
FEV1. Since these patients are susceptible to AE, a more aggressive treatment strategy is
needed in these patients.
Keywords: clustering, prognosis, phenotype, asthma-COPD overlap, exacerbation,
comorbidity
Introduction
COPD is a heterogeneous disease characterized by progressive respiratory impair-
ment and not fully reversible airway obstruction.1 Because COPD not only shows
diverse clinical manifestations and prognosis, but also requires different treatments,
multiple phenotypes are proposed to compliment this heterogeneity.2–4 Along with
the classical phenotypes of chronic bronchitis and emphysema,5 several additional
variables related to the prognosis of COPD, including severity of airway limitation,
demographics, radiographic ﬁndings, comorbidities and occurrence of acute exacer-
bation (AE) are proposed for categorization.2–4,6
Acute exacerbation of COPD (AE-COPD) is deﬁned as deterioration of respiratory
symptoms beyond normal day-to-day variations, resulting in changes of medication.7
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An AE-COPD occurs on average about 0.34–3.00 times per
person per year.8 Because AE-COPD is directly linked to
high mortality and signiﬁcant economic burden,9,10 its pre-
diction is important. The most reliable predictor of AE-
COPD is history of AE, and there is a speciﬁc patient
population with intrinsic susceptibility to AE due to expo-
sure to triggers.11 Patients who experience more than two
moderate to severe AE incidents per year are called frequent
exacerbators and have distinct characteristics including
severely impaired FEV1, dyspnea score, and physiological
score with worse outcomes.12 However, not much is known
about the speciﬁc COPD subtype associated with AE occur-
rence based on the various clinical variables related to the
occurrence of AE.
Cluster analysis is a method of data mining by deﬁning
data groups (clusters) based on measured characteristics to
identify representation in speciﬁc groups.13 Because sub-
types of COPD have commonly airﬂow limitations but
different symptoms, demographics, and prognoses, cluster
analysis is used to identify speciﬁc phenotypes.14 The aim
of this study was to identify speciﬁc COPD subtypes
through cluster analysis of variables known to be asso-
ciated with COPD prognosis and to evaluate the usefulness
of these subtypes to predict the ﬁrst AE in COPD.
Materials and methods
Study population
Among the total 2,480 subjects registered in the Korea COPD
Subgroup Study (KOCOSS) cohort recruited from 45 study
centers between December 2011 and October 2014,15 1,641
were initially screened for our study.We excluded 569 subjects
that lacked airway limitation (measured FEV1/FVC ≥0.7),
baseline pulmonary function test data, and follow-up data for
the occurrence of AE (Figure 1). Finally, 1,195 subjects with
seven clustering variables of age, body mass index (BMI),
smoking status, history of asthma, COPD assessment test
(CAT) score, post-bronchodilator (BD) FEV1% predicted,
and diffusing capacity for carbon monoxide (DLco) % pre-
dicted were enrolled. We divided the subjects into four groups
based on clustering analysis and named them according to the
characteristics of the group as follows: asthma-COPD overlap
(ACO),mildCOPD,moderate COPD, and severe COPD. This
studywas approved by the Institutional ReviewBoard of Ewha
Womans University Hospital (ECT 2012–04-006–001) and all
patients providedwritten informed consent before cohort entry.
Study design and outcomes
Data on demographics, lung function, 6MWD test,
CAT score,16 COPD-speciﬁc version of St. George’s
Respiratory Questionnaire (SGRQ) score,17 laboratory
ﬁndings, comorbidities, and medication were retrospec-
tively reviewed from electronic medical records in the
KOCOSS database. All medical data were obtained
from case-report forms evaluated by physicians or
trained nurses with 6-month interval patient examina-
tions. Spirometry and 6MWD tests were performed
according to standard American Thoracic Society
guidelines with modiﬁcation.18,19 The occurrence of
AE, deﬁned as respiratory deterioration requiring anti-
biotics or systemic corticosteroids with or without
inhaler change, was also investigated at 6-month inter-
vals by pulmonologists.
 Total 2480 subjects in korea COPD subgroup study
(KOCOSS) cohort
569 subjects were excluded due to
-high FEV1/FVC ratio (n=88)
-lack of baseline lung function test (n=11)
-insufficient follow-up data for AE (n=470)
1641 subjects were screened for cluster analysis
446 subjects were excluded due
to insufficent clustering variables
1195 subjects were finally analyzed
Variables with age,BMI,smoking
status,history of asthma,CAT score,
FEV1,DLco
Figure 1 Enrollment of patients.
Abbreviations: BMI, body mass index; DLco, diffusing capacity of the lung for carbon monoxide; CAT, COPD assessment test.
Yoon et al Dovepress
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Statistical analysis
Cluster analysis was performed using a K-means cluster
analysis with the seven variables considered to contribute
to speciﬁc COPD phenotypes.20 Clinical characteristics
were compared according to the group after clustering.
Continuous and categorical variables are expressed as
mean±SD and number (percentage), respectively. One-
way ANOVA or Kruskal–Wallis test was used for analyz-
ing continuous variables. The Pearson chi-square test or
Fisher’s exact test wasused for analyzing categorical vari-
ables. The Kaplan–Meier method was used to express AE-
free probability, and the differences between COPD
groups were assessed using the log-rank test. The risk
factors for AE including COPD subtypes were reported
as HR with 95% conﬁdence interval (CI) from the Cox’s
proportional-hazard model using time from cohort entry to
ﬁrst AE. Variables with a p-value <0.1 from univariate
analysis were candidates for multivariate analysis.
A p-value <0.05 (two-tailed) was regarded as statistically
signiﬁcant. All statistical analyses were performed using
SPSS version 24.0 (SPSS Inc., Chicago, IL, USA).
Results
Comparison of baseline demographics
Of a total of 1,195 subjects (mean age: 64.8 years, male:
92.5%), 196 (16.4%), 313 (26.2%), 345 (28.9%), and 341
(28.5%) were classiﬁed in the ACO, mild, moderate, and
severe COPD groups, respectively, mostly based on the
degree of airﬂow limitation. Among the four groups, the
ACO group had the highest proportion of male patients
(95.9% [ACO] vs 88.2% [mild] vs 94.2% [moderate] vs
93.2% [severe], p=0.004), the highest mean BMI (23.9 vs
23.7 vs 23.2 vs 21.8 kg/m2, p<0.001), and the second oldest
mean age (65.2 vs 67.7 vs 63.5 vs 63.5 years, p<0.001), while
pack-years of smoking in the ACO group was the lowest
(38.4 vs 43.3 vs 43.3 vs 47.5 pack-years, p=0.001; Table 1).
In lung function comparison, the ACO group showed
the best DLco (110.5 vs 71.6 vs 81.0 vs 49.8% predicted,
p<0.001) and 6MWD (423.9 vs 405.2 vs 389.2 vs 364.7 m,
p<0.001) values and the second-best values of FEV1 (75.5
vs 80.9 vs 52.4 vs 46.6% predicted, p<0.001), FVC (91.2
vs 95.5 vs 82.1 vs 78.8% predicted, p<0.001), and FEV1
/FVC (57.7 vs 58.4 vs 46.2 vs 43.0, p<0.001). Although
the differences were very small, the ACO group also
revealed the highest values of initial (96.5% vs 96.1% vs
96.3% vs 95.3%, p<0.003) and lowest SpO2 levels (95.6%
vs 94.7% vs 94.5% vs 92.2%, p<0.001).
In laboratory ﬁndings, total white blood cell (WBC)
count (7.2 vs 7.3 vs 7.8 vs 7.9 103/mm3, p=0.001) and
C-reactive protein (1.5 vs 5.4 vs 4.3 vs 4.7 mg/dL,
p=0.002) levels were lowest in the ACO group among
the four COPD subtypes.
Comorbidities and treatment status
Among the four COPD groups, the ACO group showed the
highest rate of gastroesophageal reﬂux disease (GERD, 16.3%
[ACO] vs 9.0% [mild] vs 10.8% [moderate] vs 6.7% [severe],
p=0.004) and the second highest rate of asthma (34.7% vs
27.2% vs 37.7% vs 34.3%, p=0.035; Table 2). Hyperlipidemia
(13.3% vs 17.0% vs 10.4% vs 9.3%, p=0.014), myocardial
infarction (5.6% vs 7.1% vs 5.5% vs 2.3%, p=0.043), and
atopic dermatitis (4.6% vs 4.8% vs 3.8% vs 2.9%) were the
highest in the mild group, followed by the ACO group.
Patients who were prescribed long-acting muscarinic
antagonist (LAMA; 57.1% vs 58.8% vs 72.9% vs 77.3%,
p<0.001) or inhaled corticosteroid (ICS) plus long-acting
beta2 agonist (LABA; 29.6% vs 21.1% vs 49.6% vs
46.1%, p<0.001) were more frequent in the moderate and
severe COPD groups compared to the ACO and mild
COPD groups (Table 3). The rates of theophylline
(33.1% vs 27.8% vs 36.6% vs 33.1%, p=0.015) and roﬂu-
milast (0.6% vs 0.4% vs 5.9% vs 0.6%, p<0.001) treat-
ments were highest in the moderate COPD group and
similar in the ACO and severe COPD groups.
Occurrence of AE
The median follow-up period was 18 months (interquartile
range: 6 to 36 months), and the ACO group had the long-
est follow-up duration (Table 4). Total number of AEs was
highest in the moderate COPD group (0.79 [ACO] vs 0.36
[mild] vs 0.90 [moderate] vs 0.86 [severe], p<0.001],
while the mean annual frequency of AE (0.29 vs 0.18 vs
0.32 vs 0.39, p<0.001) was highest in the severe COPD
group. Of total patients, 424 (35.5%) experienced AE
during the follow-up period. The median time for AE
occurrence in the ACO group was 42 months (95% CI,
28.5–55.5 months), which was similar to that of the mod-
erate COPD group (42.0 months; 95% CI, 28.3–55.7
months; Figure 2-A). The severe COPD group showed
the shortest median time for AE (30.0 months; 95% CI,
23.5–36.5 months) among the four COPD groups.
Risk factors for AE
In univariate analysis, COPD subtype, BMI, lung func-
tion test (FEV1, FVC, FEV1/FVC), lowest SpO2, CAT
Dovepress Yoon et al
International Journal of Chronic Obstructive Pulmonary Disease 2019:14 submit your manuscript | www.dovepress.com
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Table 1 Comparison of baseline characteristics according to the clustering groups
Characteristics ACO Mild Moderate Severe p-value
No 196 313 345 341
Age, years 65.2 (8.8) 67.7 (7.9) 63.5 (8.2) 63.5 (8.7) <0.001
Male 188 (95.9) 276 (88.2) 325 (94.2) 313 (93.2) 0.004
BMI, kg/m2 23.9±3.3 23.7±2.9 23.2±3.0 21.8±3.2 <0.001
Smoking status 0.852
Current 49 (25.0) 84 (26.8) 93 (27.0) 87 (25.5)
Former 126 (64.3) 195 (62.3) 214 (62.0) 226 (66.3)
Never 21 (10.7) 34 (10.9) 38 (11.0) 28 (8.2)
Smoking amount, pyrs 38.4±22.5 43.3±21.8 43.3±25.7 47.5±26.1 0.001
Lung functions test
FEV1, % predicted 75.5±16.2 80.9±12.8 52.4±10.1 46.6±12.5 <0.001
FVC, % predicted 91.2±16.7 95.5±13.8 82.1±17.1 78.8±18.0 <0.001
FEV1/FVC, % 57.7±8.7 58.4±7.5 46.2±10.7 43.0±10.6 <0.001
DLco, % predicted 110.5±16.9 71.6±12.3 81.0±9.7 49.8±11.4 <0.001
TLC, % predicted 107.4±17.6 104.0±21.5 112.3±25.7 109.5±25.9 <0.001
6MWD, meters 423.9±105.2 405.2±107.8 389.2±121.6 364.7±104.8 <0.001
Initial SpO2, % 96.5±1.9 96.1±2.2 96.3±2.4 95.3±6.4 0.003
Lowest SpO2, % 95.6±2.6 94.7±3.4 94.5±4.1 92.2±8.2 <0.001
CAT score 12.2±6.8 13.7±8.1 15.6±7.7 17.5±8.1 <0.001
SGRQ 35.1±17.9 38.7±19.4 46.6±20.8 49.4±20.2 <0.001
Laboratory ﬁndings
WBC count, 103/mm3 7.2±2.4 7.3±1.9 7.8±2.4 7.9±2.8 0.001
Eosinophil, % 3.0±2.5 3.4±2.8 3.4±3.7 3.3±3.9 0.059
CRP, mg/dL 1.5±2.9 2.0±5.4 4.3±18.6 4.7±11.4 0.002
ESR, mm/h 14.0±13.3 16.5±16.4 17.3±16.4 19.5±18.2 0.061
Note: Data are presented as mean±SD or number (%).
Abbreviations: BMI, body mass index; pyrs, pack-years; ; DLco, diffusing capacity of the lung for carbon monoxide; TLC, total lung capacity; SpO2, oxygen saturation; CAT,
COPD assessment test; SGRQ, St George’s Respiratory Questionnaire; WBC, white blood cell; CRP, C-reactive protein; ESR, erythrocyte sedimentation rate.
Table 2 Comparison of comorbidities according to the clustering groups
Characteristics ACO Mild Moderate Severe p-value
No 196 313 345 341
Hypertension 87 (44.4) 124 (39.6) 136 (39.4) 126 (37.0) 0.410
Asthma 68 (34.7) 85 (27.2) 130 (37.7) 117 (34.3) 0.035
Diabetes mellitus 38 (19.4) 62 (19.9) 59 (17.1) 44 (12.9) 0.083
GERD 32 (16.3) 28 (9.0) 37 (10.8) 23 (6.7) 0.004
Allergic rhinitis 29 (14.9) 33 (10.6) 35 (10.3) 38 (11.4) 0.393
Hyperlipidemia 26 (13.3) 53 (17.0) 35 (10.4) 32 (9.3) 0.014
Myocardial infarction 11 (5.6) 22 (7.1) 19 (5.5) 8 (2.3) 0.043
Osteoporosis 10 (5.1) 17 (5.4) 22 (6.4) 11 (3.2) 0.289
Atopic dermatitis 9 (4.6) 15 (4.8) 8 (2.4) 1 (0.4) <0.001
Heart failure 6 (3.1) 8 (2.6) 13 (3.8) 10 (2.9) 0.840
Periperal vascular disease 4 (2.0) 5 (1.6) 6 (1.7) 5 (1.5) 0.958
Thyroid disease 2 (1.0) 10 (3.2) 7 (2.1) 11 (3.2) 0.331
IBD 1 (0.5) 3 (1.0) 0 (0.0) 5 (1.5) 0.107
Note: Data are presented as number (%).
Abbreviations: GERD, gastroesophageal reﬂux disease; IBD, inﬂammatory bowel disease.
Yoon et al Dovepress
submit your manuscript | www.dovepress.com
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score, SGRQ, and total WBC count were signiﬁcantly
associated with the ﬁrst AE occurrence (Table 5). On
multivariate analysis using non-clustered variables with
a p-value <0.1, COPD subtype, SGRQ (HR, 1.019;
95% CI, 1.014–1.024; p<0.001), and GERD comorbid-
ity (HR, 1.535; 95% CI, 1.116–2.112; p=0.008) were
independent factors associated with the ﬁrst AE.
According to the multivariate Cox proportional hazard
model, the HR for the ﬁrst AE was signiﬁcantly higher
in the ACO (HR, 1.683; 95% CI 1.175–2.410;
p=0.005), moderate (HR, 1.587; 95% CI,
1.145–2.200; p=0.006), and severe (HR, 1.664; 95%
CI, 1.203–2.302; p=0.002) groups compared with the
mild group (Figure 2B).
Table 3 Comparison of treatment use according to the clustering groups
Characteristics ACO Mild Moderate Severe p-value
No 196 313 345 341
LAMA 97 (57.1) 157 (58.8) 229 (72.9) 242 (77.3) <0.001
ICS plus LABA 58 (29.6) 66 (21.1) 169 (49.6) 159 (46.1) <0.001
Theophylline 53 (33.1) 68 (27.8) 107 (36.6) 53 (33.1) 0.015
Oral beta-2 agonist 20 (12.4) 14 (5.8) 24 (8.3) 20 (12.4) 0.134
Roﬂumilast 1 (0.6) 1 (0.4) 17 (5.9) 1 (0.6) <0.001
Note: Data are presented as number (%).
Abbreviations: LAMA, long-acting muscarinic antagonist; ICS, inhaled corticosteroid; LABA, long-acting beta2 agonist.
Table 4 Number of acute exacerbation of COPD according to the clustering groups
Characteristics ACO Mild Moderate Severe p-value
No 196 313 345 341
Follow-up duration, months 24 (12–36) 12 (6–24) 18 (6–30) 18 (12–36) <0.001
Total number of AE 0.79±1.42 0.36±1.01 0.90±1.58 0.86±1.37 <0.001
Number of AE per year 0.29±0.49 0.18±0.51 0.32±0.49 0.39±0.58 <0.001
Note: Data are presented as mean±SD or median (interquartile range).
Abbreviations: AE, acute exacerbation; mo, month.
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Figure 2 Survival curve for acute exacerbation. (A) Kaplan–Meier curves showed the proportion of acute exacerbation free patients for four COPD subgroups. (B)
Multivariate Cox survival curves showed the proportion of acute exacerbation free patients for four COPD subgroups.
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Discussion
Using age, BMI, smoking status, history of asthma, CAT
score, FEV1, and DLco variables in clustering, we divided
patients into the following four subtypes: ACO, mild,
moderate, and severe COPD. The ACO group had
the second-best FEV1 and FVC values and the highest
BMI and DLco. The ACO group also showed the lowest
CAT and SGRQ scores and higher rates of asthma and
GERD as comorbidities. The COPD subtypes were an
independent predictor for ﬁrst occurrence of AE with
SGRQ and GERD, and our ACO group showed
a signiﬁcant 76.6% increase in the rate of AE, with
65.9% and 69.6% increases in the moderate and severe
groups, respectively, compared with the mild group.
Our study demonstrated that phenotype is linked to the
occurrence of AE through clustering analysis using seven
clinical variables without the history of AE. Previous studies
identiﬁed the frequent exacerbator phenotype based on the
history of AE, because a history of AE is the most powerful
predictor of AE.11,12,21 The Exacerbations of COPD Patients
(EXACO) study revealed the frequent exacerbator pheno-
type to have more impaired airﬂow limitation, respiratory
symptoms, and daily activity limitations according to four-
year follow-up of AE frequency.12 In the Evaluation of
COPD Longitudinally to Identify Predictive Surrogate
Endpoints (ECLIPSE) study, frequent exacerbators also
showed rapid decline in FEV1, the rate of GERD or heartburn
symptoms, and elevated WBC counts compared with non-
Table 5 Univariate and multivariate Cox analysis of risk factors associated with AE occurrence
Characteristics Univariate analysis Multivariate analysis
HR 95% CI p-value HR 95% CI p-value
Subgroup
Mild 1.000 1.000
ACO 1.605 1.146–2.246 0.006 1.683 1.175–2.410 0.005
Moderate 1.989 1.484–2.668 <0.001 1.587 1.145–2.200 0.006
Severe 1.691 1.256–2.277 0.001 1.664 1.203–2.302 0.002
Age, years 0.994 0.984–1.004 0.217
Male 0.881 0.666–1.166 0.376
BMI, kg/m2 0.976 0.952–1.000 0.047
Smoking status
Current 1.000
Former 0.978 0.812–1.179 0.818
Never 1.034 0.782–1.368 0.812
Smoking amount, pyrs 1.002 0.999–1.005 0.279
FEV1, % predicted 0.984 0.980–0.988 <0.001
FVC, % predicted 0.994 0.990–0.998 0.004 1.001 0.995–1.007 0.691
FEV1/FVC, % 0.976 0.970–0.983 <0.001
DLco, % predicted 0.999 0.995–1.003 0.661
TLC, % predicted 1.002 0.998–1.005 0.360
6MWD, meters 0.999 0.999–1.000 0.093 1.000 0.999–1.001 0.810
Initial SpO2, % 0.997 0.968–1.027 0.852
Lowest SpO2, % 0.984 0.969–0.999 0.032 0.991 0.968–1.015 0.471
CAT score 1.041 1.030–1.051 <0.001
SGRQ 1.018 1.014–1.022 <0.001 1.019 1.014–1.024 <0.001
Asthma 0.924 0.783–1.089 0.345
GERD 1.279 1.000–1.637 0.050 1.535 1.116–2.112 0.008
WBC count, 103/mm3 1.066 1.034–1.099 <0.001 1.031 0.987–1.077 0.166
CRP, mg/dL 0.997 0.983–1.011 0.677
ESR, mm/h 1.001 0.994–1.008 0.871
Abbreviations: BMI, body mass index; DLco, diffusing capacity of the lung for carbon monoxide; TLC, total lung capacity; SpO2, oxygen saturation; CAT, COPD assessment
test; SGRQ, St George’s Respiratory Questionnaire; GERD, gastroesophageal reﬂux disease; WBC, white blood cell; CRP, C-reactive protein; ESR, erythrocyte sedimenta-
tion rate.
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frequent exacerbators.11 However, the subtype related to the
occurrence of AE based on clustering in our study showed
mild airway limitation and respiratory symptoms and rela-
tively high rates of asthma and GERD as comorbidities.
These results suggest that, in addition to other factors
known to be associated with AE, the ACO subtype of
COPD seems to have a relationship with AE occurrence.
The reason we named one of the four clusters as
a putative “ACO” group in this study is as follows.
Diagnosis of ACO requires partial but not complete reversi-
bility of airway limitation (post-BD FEV1<80% predicted).
22
Non-impairment of DLco with post-BD FEV1<80%
predicted in the putative ACO group could be evidence for
non-existing emphysema. Among the four groups,
the second-most common underlying diseases, asthma and
atopic dermatitis, also supported the possibility of ACO.23 In
clinical practice, the diagnosis of ACO, which indicates
coexisting COPD and asthma, is challenging because the
standard validated diagnostic criteria are still
controversial.24 ACO patients are generally reported to
have more frequent AE compared with pure COPD or
asthma.25–28 However, ACO patients in a previous study
showed relatively severe airway limitation with impaired
baseline post-BD FEV1, which is a strong risk factor for
AE.11 In our study, the putative ACO subtype had moderate
airway limitation but a high rate of AE-COPD. In addition,
our ACO group showed different characteristics from the
ACO groups as deﬁned in other studies, showing a low
level of inﬂammatory markers and modest airway limitation
and preserved functional capacity.27–29 In addition, better
dyspnea scale score and functional parameters in the ACO
group are also unique to our study compared with those in
other studies. These results suggest that other factors are
related to the occurrence of AE in addition to the conven-
tional COPD severity indicators.
According to our study, the putative ACO group had the
highest proportion of patients with GERD but lower propor-
tions of patients who received LAMA and ICS plus LABA
treatment due to mild airway limitation. The high AE occur-
rence rate in the ACO group might be attributed to the high
presence of GERD despite relatively mild impairment of lung
function. Several studies have reported that GERD is an inde-
pendent risk factor for AE-COPD.11,30–35 In the ECLIPSE
study, AE-COPD was linked to the history of GERD or heart-
burn with prior history of AE.11 Meta-analysis based on ﬁve
prospective and retrospectiveCOPDstudies also demonstrated
that the risk of AE-COPD was signiﬁcantly increased in
patients with GERD (relative risk: 7.57; 95% CI,
3.57–14.94).30 Martinez et al demonstrated a signiﬁcant rela-
tionship between the frequent exacerbator phenotype (≥2
COPD-AE per year) and GERD (odds ratio, 1.40;
p=0.006).35 However, since most COPD patients with GERD
rarely complain of either reﬂux symptoms (eg, heartburn,
regurgitation) or respiratory symptoms (eg, cough,
dyspnea),36 there is a possibility that GERD diagnosis often
is overlooked. Silent aspiration of gastric contents due to
GERDmight lead to frequent AE-COPD by increasing bacter-
ial burden in the respiratory tract.37 Sasaki et al showed that
anti-reﬂux treatment signiﬁcantly reduced the occurrence of
AE in COPD patients without reﬂux symptoms,38 indicating
that management of GERD could be beneﬁcial for preventing
AE-COPD.
Another reason for the high incidence of AE in our
putative ACO group might be the low administration of
ICS plus LABA, despite the relatively high proportion of
asthma. Current Global Initiative for Asthma management
guidelines recommend regular use of low-dose ICS as
initial treatment for symptomatic asthma patients.
Furthermore, if the predominance of asthma and COPD
in ACO patients is difﬁcult to determine, ﬁrst-line treat-
ment should include ICS, followed by addition of other
inhalers if needed.39 In our study, ICS usage in the ACO
group was low, which might be due to mild impairment of
lung function, good exercise capacity, and low symptom
score. While the ACO group in our study was an indepen-
dent factor for ﬁrst AE occurrence, the annual incidence of
AE was highest in the severe group. Although we did not
collect data on changes in medication during follow-up,
these ﬁndings suggest that the ACO group might have
experienced inhibition of further development of AE by
appropriate treatment such as ICS after occurrence of the
ﬁrst AE event.
The limitations of our study are as follows. First, AE in
our study was not based on strict criteria since this was
a retrospective cohort study. The accurate time, severity,
and clinical course of AE were not evaluated. However,
the occurrence of AE was carefully assessed by experi-
enced pulmonologists, and all patients were evaluated at
6-month intervals. Second, the relatively short follow-up
duration might result in underestimated AE occurrence;
however, since the annual exacerbation frequency ranged
from two to three times per year depending on the severity
of COPD,40 the median 18-month follow-up duration
might be sufﬁcient to assess the ﬁrst development of AE.
Lastly, subjects excluded due to insufﬁcient follow-up data
(n=470) might have led to selection bias. It was not
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possible to assume the cause of follow-up loss, but it
might be another reason for underestimation of AE
development.
Conclusion
In conclusion, we identiﬁed the COPD subtypes susceptible to
AE using cluster analysis with several clinical factors, includ-
ing lung function. The ACO group had frequent AE-COPD
despite good pulmonary function and exercise capacity and
low dyspnea scale, which might be associated with GERD.
Thus, subtypes susceptible to AE need more aggressive treat-
ment strategies considering their comorbidities. Further stu-
dies should highlight the speciﬁc phenotype related to
mortality or lung function decline in COPD patients.
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